Expression of oral secretory leukocyte protease inhibitor in HIV-infected subjects with long-term use of antiretroviral therapy

Journal of Oral Pathology and Medicine

Volumn 42, Issue 3, 2013, Pages 208-215

  Nittayananta, Wipawee ^a   Kemapunmanus, Marisa ^a   Yangngam, Supaporn ^a   Talungchit, Sineepat ^b   Sriplung, Hutcha ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b SRINAKHARINWIROT UNIVERSITY   (Thailand)

Author keywords

ART; HIV; Oral health; Oral lesion; Risk factor; Secretory leukocyte protease inhibitor

Indexed keywords

ANTIRETROVIRUS AGENT; MESSENGER RNA; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MOUTH; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD;

ADULT; ALCOHOL DRINKING; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; GINGIVAL HEMORRHAGE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; ORAL HEALTH; PERIODONTAL POCKET; SALIVA; SALIVARY PROTEINS AND PEPTIDES; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SECRETORY RATE; SERINE PROTEINASE INHIBITORS; SMOKING; TIME FACTORS; VIRAL LOAD; YOUNG ADULT; ZIDOVUDINE;

EID: 84874719122     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12023     Document Type: Article

References (37)

1. Dale BA, Fredericks LP. Antimicrobial peptides in the oral environment: expression and function in health and disease. Curr Issues Mol Biol 2005; 7: 119-33.
2. Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci U S A 1986; 83: 6692-96.
3. Franken C, Meijer CJ, Dijkman JH. Tissue distribution of antileukoprotease and lysozyme in humans. J Histochem Cytochem 1989; 37: 493-98.
4. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96: 456-64.
5. Song X, Zeng L, Jin W, et al. Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J Exp Med 1999; 190: 535-42.
6. Zhu J, Nathan C, Jin W, et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002; 111: 867-78.
7. Zhang D, Simmen RC, Michel FJ, Zhao G, Vale-Cruz D, Simmen FA. Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes. J Biol Chem 2002; 277: 29999-30009.
8. Wen J, Nikitakis NG, Chaisuparat R, et al. Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma. Am J Pathol 2011; 178: 2866-78.
9. Challacombe SJ, Naglik JR. The effects of HIV infection on oral mucosal immunity. Adv Dent Res 2006; 19: 29-35.
10. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society USA panel. JAMA 2008; 300: 555-70.
11. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr. Changing prevalence of oral manifestations of human immune-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89: 299-304.
12. Nokta M. Oral manifestations associated with HIV infection. Curr HIV/AIDS Rep 2008; 5: 5-12.
13. Miziara ID, Weber R. Oral lesions as predictors of highly active antiretroviral therapy failure in Brazilian HIV-infected children. J Oral Pathol Med 2008; 37: 99-106.
14. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-32.
15. Gillison ML. Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol 2009; 21: 439-44.
16. Olivero OA. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Environ Mol Mutagen 2007; 48: 215-23.
17. EC-Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus. Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med 1993; 22: 289-91.
18. Shiboski CH, Patton LL, Webster-Cyriaque JY, et al. The Oral HIV/AIDS Research Alliance: updated case definitions of oral disease endpoints. J Oral Pathol Med 2009; 38: 481-8.
19. Nittayananta W, Talungchit S, Jaruratanasirikul S, et al. Effects of long-term use of HAART on oral health status of HIV-infected subjects. J Oral Pathol Med 2010; 39: 397-406.
20. Nittayananta W, Hladik F, Klausner M, Harb S, Dale BA, Coombs RW. HIV type 1 fails to trigger innate immune factor synthesis in differentiated oral epithelium. AIDS Res Hum Retroviruses 2009; 25: 1013-21.
21. Baqui AA, Meiller TF, Falkler WA Jr. Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol 1999; 6: 808-11.
22. Lin AL, Johnson DA, Stephan KT, Yeh CK. Salivary secretory leukocyte protease inhibitor increases in HIV infection. J Oral Pathol Med 2004; 33: 410-6.
23. Nittayananta W, Kemapunmanus M, Amornthatree K, Talungchit S, Sriplung H. Oral human β-defensin 2 in HIV-infected subjects with long-term use of antiretroviral therapy. J Oral Pathol Med 2012; doi: 10.1111/j.1600-0714.2012.01183.x (in press).
24. McCullough M, Jaber M, Barrett AW, Bain L, Speight PM, Porter SR. Oral yeast carriage correlates with presence of oral epithelial dysplasia. Oral Oncol 2002; 38: 391-3.
25. Field EA, Field JK, Martin MV. Does Candida have a role in oral epithelial neoplasia? J Med Vet Mycol 1989; 27: 277-94.
26. Moreau T, Baranger K, Dadé S, Dallet-Choisy S, Guyot N, Zani ML. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 2008; 90: 284-95.
27. Diamond G, Ryan L. Beta-defensins: what are they really doing in the oral cavity?. Oral Dis 2011; 17: 628-35.
28. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006; 7: 167-74.
29. Zhang Y, DeWitt DL, McNeely TB, Wahl SM, Wahl LM. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest 1997; 99: 894-900.
30. Schaaij-Visser TB, Bremmer JF, Braakhuis BJ, et al. Evaluation of cornulin, keratin 4, keratin 13 expression and grade of dysplasia for predicting malignant progression of oral leukoplakia. Oral Oncol 2010; 46: 123-7.
31. Simard EP, Pfeiffer RM, Engels EA. Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med 2010; 170: 1337-45.
32. Bedimo R. Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era. Curr HIV/AIDS Rep 2008; 5: 140-9.
33. Adler DH. The impact of HAART on HPV-related cervical disease. Curr HIV Res 2010; 8: 493-7.
34. Joly S, Compton LM, Pujol C, Kurago ZB, Guthmiller JM. Loss of human beta-defensin 1, 2, and 3 expression in oral squamous cell carcinoma. Oral Microbiol Immunol 2009; 24: 353-60.
35. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95: 1772-83.
36. Mork J, Lie AK, Glattre E, Hallmans G, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344: 1125-31.
37. Amornthatree K, Sriplung H, Mitarnun W, Nittayananta W. Impacts of long-term use of antiretroviral therapy on the prevalence of oral human papilloma virus type 16. J Oral Pathol Med 2012; 41: 309-14.